B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common type of cancer in children, representing up to 80% of pediatric, and \~20% of adult leukemias.^[@bib1]^ BCP-ALL is divided into several genetic subtypes according to acquired chromosomal aberrations with varying prognosis.^[@bib2]^ In children and young adults, BCP-ALL patients have an overall survival (OS) at 5 years around 90%. In contrast, OS in adults is much lower (30--40%), in part due to a higher frequency of ALL subtypes with poor prognosis.^[@bib3],\ [@bib4]^ Hence, identifying new biomarkers for patients with poor prognosis is important as it might allow the development of new approaches to treat high-risk BCP-ALL.

CD27 is a member of the tumor necrosis factor receptor superfamily that regulates lymphocyte function.^[@bib5]^ Expression of CD27 protein and mRNA has been reported in B-cell lymphomas ^[@bib6]^ and adult T-cell leukemia/lymphoma.^[@bib7]^ In acute myeloid leukemia CD27 has been shown to be a prognostic biomarker.^[@bib8]^ We previously described a pro-B-cell molecular signature enriched in the *ETV6-RUNX1* subtype, and found that one of these genes is CD27.^[@bib9]^ Consistent with this, previous studies have shown high mRNA and surface levels of CD27 in *ETV6-RUNX1* BCP-ALL.^[@bib10],\ [@bib11]^ However, expression of CD27 in BCP-ALL of other subtypes and its potential clinical relevance is still unclear. Here, we determine the protein and mRNA expression pattern of CD27 during early B-cell development and in BCP-ALL, and investigate the prognostic relevance of *CD27* mRNA expression in pediatric and adult patients with BCP-ALL.

To confirm and extend previous observations,^[@bib10],\ [@bib11],\ [@bib12]^ we first analyzed CD27 expression during bone marrow (BM) B-cell development using flow cytometry (gating strategy, [Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}). Pro-B cells (CD19^+^CD34^+^IgM^−^) from all five donors expressed CD27, whereas common lymphoid progenitor (CLP, CD19^−^CD34^+^IgM^−^), pre-B (CD19^+^CD34^−^IgM^−^) and immature B (CD19^+^CD34^−^IgM^+^) cells did not ([Figures 1a and b](#fig1){ref-type="fig"}, [Supplementary Figure S1b](#sup1){ref-type="supplementary-material"}). We also noted that only a fraction, on average 25%, of the pro-B cells were positive ([Figure 1b](#fig1){ref-type="fig"}). Thereafter, we analyzed six patient samples, of which two expressed CD27 at the time of diagnosis ([Figure 1c](#fig1){ref-type="fig"} and [Supplementary Figure S1c](#sup1){ref-type="supplementary-material"}). The CD27 levels in these two cases, classified as B-other, were much higher than those in the healthy pro-B cells, with the vast majority of the CD19^+^ leukemic cells being strongly positive. Consistent with the CD27 protein expression pattern, we found that *CD27* mRNA levels were high in pro-B cells as compared to CLP, pre-B and immature B cells ([Figure 1d](#fig1){ref-type="fig"}). To determine which BCP-ALL subtypes express *CD27* we analyzed its mRNA levels in public data sets ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). In pediatric leukemia samples, for example, data set GSE26281, *CD27* was as expected highly expressed in over 90% of *ETV6-RUNX1,* compared to the mean level of the total samples (*M*~0~) ([Figure 1e](#fig1){ref-type="fig"}). In addition, more than half of *BCR-ABL1* and *CRLF2*-rearranged, and a third of B-other BCP-ALL also expressed high levels of *CD27* mRNA. In adult BCP-ALL, for example, data set GSE34861, *CD27* was highly expressed in more than 60% of *BCR-ABL1* and on average in 45% of B-other BCP-ALL compared to the mean level of the total samples (*M*~0~) in each data set ([Figure 1f](#fig1){ref-type="fig"}). Thus, *CD27* is not only highly expressed in the *ETV6-RUNX1,* but also in *BCR-ABL1*, CRLF2-rearranged and B-other BCP-ALL.

The *CRLF2*-rearranged subtype was only recently defined^[@bib13],\ [@bib14]^ and, therefore, these patient samples are found within B-other in most public data sets. To determine the *CRLF2*-rearranged subtype in data sets where this has not been defined, the *CRLF2* expression levels in already defined *CRLF2*-rearranged samples ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}, GSE26281 and GSE11877) were analyzed. We found that the expression levels of *CRLF2* in all *CRLF2*-rearranged samples were at least 10-fold higher than the median levels of total samples ([Supplementary Figure S2a](#sup1){ref-type="supplementary-material"}). Based on this, samples expressing 10-fold higher level of *CRLF2* than the median are referred to as *CRLF2*-*high* in other data sets ([Supplementary Figure S2b](#sup1){ref-type="supplementary-material"}) with the assumption that most of these are *CRLF2*-rearranged. Thereafter, we queried which subtypes were enriched in samples with high *CD27* expression levels, by performing meta-analyses based on eight data sets with over 1500 pediatric patient samples in total and two data sets with over 250 adult patient samples ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Samples in each data set were first divided into four clusters (*CD27*^++^, *CD27*^+^, *CD27*^−^ and *CD27*^−−^) according to *CD27* mRNA levels ([Supplementary Figure S2c](#sup1){ref-type="supplementary-material"}) and thereafter pooled. Subtype distribution analysis in pediatric BCP-ALL showed that *ETV6-RUNX1, BCR-ABL1* and *CRLF2*-rearranged/*high* were proportionally enriched in the *CD27*^++^ and *CD27*^+^ clusters, whereas the opposite was observed for, for example, *KMT2A-*rearranged ([Figure 1g](#fig1){ref-type="fig"}). Also in adult samples, the *BCR-ABL1* subtype was enriched in the *CD27*^++^ and *CD27*^+^ clusters, and the opposite was observed for, for example, *KMT2A-*rearranged ([Figure 1h](#fig1){ref-type="fig"}). Thus, pediatric and adult BCP-ALL showed similar expression patterns of *CD27*.

Because *CD27* mRNA is highly expressed in the *ETV6-RUNX1* subtype that display a pro-B-cell molecular signature,^[@bib9]^ we hypothesized that BCP-ALL samples with high *CD27* mRNA levels would also display a pro-B signature ([Figure 1i](#fig1){ref-type="fig"}). To test this hypothesis, we performed gene set enrichment analyses (GSEA) in leukemia data sets after excluding the *ETV6-RUNX1* subtype. Independent of genetic subtype, pediatric BCP-ALL expressing high *CD27* mRNA levels (*CD27*^++^) showed a molecular signature similar to pro-B cells ([Figure 1j](#fig1){ref-type="fig"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). However, we were unable to find a pro-B signature in adult BCP-ALL, which indicates that the molecular signature is different in children and adults.

Since *CD27* mRNA was highly expressed in BCR-ABL1 and *CRLF2-*rearranged/*high* BCP-ALL that are associated with poor prognosis, we asked whether *CD27* has prognostic value. To determine this, we first analyzed clinical data available from 207 high-risk pediatric BCP-ALL patients ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}, GSE11877). Dividing the patient samples into four clusters according to *CD27* expression levels, we found that the *CD27*^++^ cluster was associated with poor OS compared with the other clusters ([Figure 2a](#fig2){ref-type="fig"}). Moreover, approximately 60% of patients in the *CD27*^++^ cluster had relapse compared to 25--30% in the remaining clusters ([Figure 2b](#fig2){ref-type="fig"}). Thus, *CD27* expression levels correlate with clinical outcome in this cohort with high-risk pediatric BCP-ALL patients. To further confirm this observation, we analyzed the clinical data available from an additional pediatric cohort including 75 patients ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}, GSE47051). Because the *ETV6-RUNX1* subtype is associated with good prognosis in pediatric BCP-ALL,^[@bib2]^ we excluded this subtype in the analyses. We did not detect a significant difference in OS between the clusters ([Figure 2c](#fig2){ref-type="fig"}), whereas a significantly lower OS was observed in the combined *CD27*^++*/*+^ compared to the *CD27*^−/*−−*^ clusters ([Figure 2c](#fig2){ref-type="fig"}). There was also a trend for a higher proportion of relapse in the former ([Figure 2d](#fig2){ref-type="fig"}). We also analyzed the prognostic relevance of *CD27* expression levels in adults with BCP-ALL in the cohort with available clinical data ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}, GSE34861). This showed significantly different OS for patients in the *CD27* clusters ([Figure 2e](#fig2){ref-type="fig"}). Thus, this suggests that *CD27* could be a marker for poor prognosis for non-*ETV6-RUNX1* BCP-ALL both in children and adults. Our observation is in contrast to a previous study that did not find any significant differences in OS between CD27 positive and negative BCP-ALL.^[@bib11]^ However, this previous study included a low proportion of high-risk patients, and the follow-up time was shorter than 3 years. In our study, all the cohorts included at least a fifth of high-risk BCP-ALL, and the follow-up time was much longer than 3 years.

In B-other BCP-ALL with unknown or not classifying genetic aberrations there are few prognostic biomarkers. As *CD27* showed differential expression pattern in B-other BCP-ALL, we asked whether *CD27* could also be used as a marker for these types of leukemia. To investigate this, the clinical data from patients with B-other BCP-ALL in the above cohorts were analyzed. In the high-risk cohort (GSE11877) with 126 B-other samples, *CD27*^*++*^ mRNA levels were associated with poor OS ([Figure 2f](#fig2){ref-type="fig"}), and 60% of patients in the *CD27*^++^ cluster experienced relapse compared to 25--35% in the remaining clusters ([Figure 2g](#fig2){ref-type="fig"}). In the other pediatric cohort (GSE47051) with only 23 B-other samples, the *CD27*^*++/+*^ cluster showed a trend to poor OS ([Supplementary Figure S4a](#sup1){ref-type="supplementary-material"}). In addition, in adults with B-other BCP-ALL, the *CD27*^*++/+*^ cluster also showed a trend to poor OS ([Supplementary Figure S4b](#sup1){ref-type="supplementary-material"}). Taken together, these data demonstrate that high *CD27* levels represent a poor prognostic marker for high-risk pediatric B-other BCP-ALL.

In conclusion, our findings that *CD27* is highly expressed in high-risk pediatric and adult BCP-ALL indicates that this molecule might serve as a therapeutic target, especially for the *BCR-ABL1, CRLF2-*rearranged/*high* and B-other subtypes. A human anti-CD27 monoclonal antibody has been developed, and *in vitro* and *in vivo* studies have shown that this antibody can exert anti-tumor activity in lymphoma xenograft models.^[@bib15]^ Future studies will concentrate on determining whether CD27 can indeed be used as diagnostic/prognostic markers, and whether anti-CD27 antibodies can be used to directly target BCP-ALL expressing surface CD27.
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Comparison of CD27 expression and molecular signature between pro-B cells and BCP-ALL. (**a**) Representative histogram shows surface CD27 expression in pro-B cells. (**b**) Scatter plot shows percentages of CD27^+^ cells in indicated subsets of BM samples from five healthy donors. (**c**) Representative histograms show CD27 surface expression in two BCP-ALL samples (CD27^+^ and CD27^−^). (**d**, **e**, **f**) Heat maps and scatter plots show *CD27* mRNA expression levels in (**d**) healthy (GSE45460) BM; (**e**) pediatric (GSE26281) and (**f**) adult (GSE34861) BCP-ALL samples. Dashed line in scatter plots represents *M*~0~. (**g** and **h**) Pie charts show the proportions of BCP-ALL subtypes within each *CD27* cluster based on meta-analyzes of (**g**) eight pediatric data sets (GSE26281, GSE33315, GSE13576, GSE13425, GSE12995, Blood 2003, GSE11877, GSE47051) and (**h**) two adult data sets (GSE34861 and CCR 2005), after classifying BCP-ALL samples in each data set into four groups according to *CD27* expression levels: *CD27*^++^ (\>*M*~1~), *CD27*^+^ (\<*M*~1~ to \>*M*~0~), *CD27*^−^ (\<*M*~0~ to \>*M*~−1~), *CD27*^−−^ (\<*M*~−1~). Numbers in the center of pie charts represent number of patient samples, and those in segments the proportions of the indicated subtype. *M*~0~: mean expression level of *CD27* in all samples; *M*~1~: mean expression of *CD27* in samples with levels above *M*~0~; *M*~−1~: mean expression of *CD27* in samples with levels below *M*~0~. (**i**) Heat map shows genes highly expressed in pro-B cells (pro-B signature). Genes are selected according to the criteria: *P*-value (\<0.05), *q*-value (\<0.1) and fold change (\>1.5). (**j**) Heat map (left) and GSEA enrichment plots (right) reveals a pro-B molecular signature in *CD27*^*++*^ high-risk pediatric BCP-ALL data set (GSE11877). CLP, common lymphoid progenitor; iB, immature B. ^\#^*CRLF2*-rearranged (previously defined) and *CRLF2-high* (defined herein) were pooled. Statistical analysis: (**b** and **d**) one-way ANOVA and (**g** and **h**) *χ*^2^ analysis. \*\**P* \< 0.01; \*\*\**P*\<0.001; \*\*\*\**P*\<0.0001.
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![Clinical relevance of *CD27* mRNA levels in patients with BCP-ALL. (**a**, **c**, **e**, **f**) Kaplan--Meier Log-rank survival analysis was used to compare survival of patients within the indicated *CD27* clusters. (**b**, **d**, **g**) Percentages of patients with relapse within indicated *CD27* clusters using Fisher\'s exact test. (**a**, **b**) High-risk pediatric cohort GSE118877, (**c**, **d**) pediatric cohort GSE47051 (excluding *ETV6-RUNX1*); *CD27*^++/+^, *CD27*^++^ and *CD27*^+^; *CD27*^-/---^, *CD27*^−^ and *CD27*^−−^, (**e**) adult cohort GSE34861 and (**f**, **g**) B-other patients within high-risk pediatric cohort GSE118877.](bcj201755f2){#fig2}
